載入中
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
前收盤價
US$3.04
−US$0.1786 · -5.55%
盤前
US$2.98
−US$0.06 · -1.97%
10月13日 上午7:36 ET
盤中時間採用ET。市場資料可能有所延遲。
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
日內區間
目前US$3.04
52週區間
目前US$3.04
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
強力賣出
估值
2
估值過高
情緒
45
多空交錯
風險
82
極高風險
動能
31
動能減弱
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Addex Therapeutics Ltd, a biopharmaceutical firm in a developmental phase, operates out of Switzerland, focusing on the discovery, advancement, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. Their core strategy involves identifying oral small-molecule allosteric modulators for G-protein coupled receptors. The company's key programs include Dipraglurant, an investigational treatment for Parkinson's disease levodopa-induced dyskinesia and dystonia; ADX71149, which is being developed for epilepsy and other unspecified CNS conditions; and GABAB PAM, a compound aimed at treating addiction. Addex Therapeutics has established licensing and collaboration agreements with significant partners, including Janssen Pharmaceuticals Inc., Indivior PLC, and The Charcot–Marie–Tooth Association. Founded in 2002 and based in Geneva, Switzerland, the company was initially known as Addex Pharmaceuticals Ltd before officially changing its name to Addex Therapeutics Ltd in March 2012.
日內區間
目前US$3.04
52週區間
目前US$3.04
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CHF） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3萬 CHF | 40.41萬 CHF | 161.3萬 CHF | 142.24萬 CHF | 291.63萬 CHF |
| 毛利 | 3萬 CHF | 40.41萬 CHF | 161.3萬 CHF | 142.24萬 CHF | 291.63萬 CHF |
| 研究與開發 | 19.02萬 CHF | 43.52萬 CHF | 94.27萬 CHF | 788.35萬 CHF | 901.41萬 CHF |
| 銷售、一般及管理費用 | 188.79萬 CHF | 167.52萬 CHF | 203.1萬 CHF | 326.2萬 CHF | 774.63萬 CHF |
| 營業費用 | 284.46萬 CHF | 315.93萬 CHF | 385.59萬 CHF | 1196.33萬 CHF | 1842.22萬 CHF |
| 利息收入 | — | 9165 CHF | 6.4萬 CHF | 2.93萬 CHF | 5322 CHF |
| 利息支出 | 2421 CHF | 3547 CHF | 2.16萬 CHF | 4.89萬 CHF | 6.3萬 CHF |
| 折舊和攤銷 | 8472 CHF | 26.01萬 CHF | 30.6萬 CHF | 32.31萬 CHF | 34.76萬 CHF |
| 營業利益 | −281.46萬 CHF | −275.52萬 CHF | −224.3萬 CHF | −1054.09萬 CHF | −1550.59萬 CHF |
| 淨利 | −672.82萬 CHF | 705.58萬 CHF | −1055.62萬 CHF | −2080.42萬 CHF | −1535.19萬 CHF |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
| 行動 | 生效日期 | 詳情 | 記錄日期 | 付款日期 |
|---|---|---|---|---|
股票分割 | 2023年10月23日 | 1:20 | — | — |
已生效 2023年10月23日
1:20
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
